Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).

Framingham, Massachusetts-based Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging (NIA), part of the National Institutes of Health, to assist with a Phase III clinical trial of ALZ-801.

Shares of Biogen jumped more than 11 percent after the company announced the U.S. Food and Drug Administration accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.

Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership came to an end after AbbVie terminated the agreement.

A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.

Brussels, Belgium-based UCB entered into a global licensing deal with Roche and Genentech to develop and commercialize UCB0107 in Alzheimer’s disease.

In a review of recently published scientific studies, researchers with Queen Mary University of London discovered a gene that naturally suppresses the signs of Alzheimer’s disease in human brain cells.

AC Immune initiated the second highest dosing group in the company’s Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease, based on encouraging interim data from the initial dosing cohort.

The U.S. Food and Drug Administration approved drugmaker Eli Lilly and Co.’s radioactive compound to detect tau, an important characteristic of Alzheimer’s disease.

75 top Alzheimer’s and dementia experts collaborated on a 10-year strategic plan for researchers, policymakers and caregivers   May 21, 2020 –– A new report released today by AARP and the Women’s Alzheimer’s Movement (WAM) synthesizes years of data and findings to help explain why women are disproportionately affected by Alzheimer’s disease. Two-thirds of the 5.8 […]